Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/1999
11/09/1999US5980895 Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
11/09/1999US5980884 Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
11/09/1999US5980881 Medicament for preventive and/or therapeutic treatment of hyperphosphatemia
11/09/1999US5980867 An inhalants comprising flunisolide, ethanol, and a propellant selected from 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane for treating bronchial asthma
11/09/1999US5980865 Administering to the patient of a pharmaceutical composition containing about 0.005 to about 1.0 mg of ultra-low molecular weight heparins
11/09/1999US5980827 Passing air containing airborne microorganisms through air path means and disinfecting air in said path means by passing air over demand disinfectant resin such that airborne microorganisms contact said resin and are devitalized thereby,
11/09/1999US5980477 Genital lubricants with zinc salts as anti-viral additives
11/09/1999CA2177780C New arylalkyl(thio)carboxamide compounds, their preparation processes and the pharmaceutical compositions that contain them
11/09/1999CA2157750C Photocleavable sequestering agents and compositions thereof
11/09/1999CA2106452C Amidinophenol derivatives
11/09/1999CA2102321C Partial liquid breathing of fluorocarbons
11/09/1999CA2065111C Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention
11/09/1999CA2024642C Water-containing external preparations
11/09/1999CA2008126C Low dose benazepril/thiazide diuretic composition
11/09/1999CA2004239C Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment
11/06/1999CA2270847A1 Alpha-ketoamide derivatives
11/04/1999WO1999055903A1 Membrane-permeant phosphoinositides
11/04/1999WO1999055900A2 Gcp
11/04/1999WO1999055898A1 Enzymatic resolvation for obtaining a (-)-3,4-trans-diarylchroman
11/04/1999WO1999055873A2 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
11/04/1999WO1999055855A2 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
11/04/1999WO1999055854A2 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth
11/04/1999WO1999055847A2 Enzymatic nucleic acids molecules which modulate the expressions and/or replication of hepatitis c virus
11/04/1999WO1999055845A1 Cellular and animal models for diseases associated with altered mitochondrial function
11/04/1999WO1999055830A2 Process for synthesizing cox-2 inhibitors
11/04/1999WO1999055733A1 Cloning of a novel 7tm receptor axor-2
11/04/1999WO1999055729A1 STAPHYLOCOCCUS AUREUS pyrH POLYPEPTIDES AND POLYNUCLEOTIDES
11/04/1999WO1999055713A1 Phosphonic diester derivatives
11/04/1999WO1999055711A1 Treatment of mastitis
11/04/1999WO1999055708A1 Condensed thienopyrimidines with phosphodiesterase-v inhibiting action
11/04/1999WO1999055706A1 Imidazo pyridine derivatives which inhibit gastric acid secretion
11/04/1999WO1999055705A1 Imidazo pyridine derivatives which inhibit gastric acid secretion
11/04/1999WO1999055704A1 Pharmaceutically available protoberberine salts derivatives, and protoberberine derivatives and salts thereof
11/04/1999WO1999055701A1 Process for making 1,3-disubstituted-4-oxocyclic ureas
11/04/1999WO1999055700A1 Process for making 1,3-disubstituted-4-oxocyclic ureas
11/04/1999WO1999055699A1 Paroxetine 10-camphorsulfonate for treatment of cns disorders
11/04/1999WO1999055698A1 Paroxetine ascorbate
11/04/1999WO1999055697A1 Serotonergic agents
11/04/1999WO1999055696A1 New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
11/04/1999WO1999055695A1 Indolyl derivatives as serotonergic agents
11/04/1999WO1999055694A1 Indolyl derivatives as serotonergic agents
11/04/1999WO1999055690A1 Guanidine derivatives
11/04/1999WO1999055686A2 Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
11/04/1999WO1999055683A1 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
11/04/1999WO1999055682A1 Methods of identifying and using hla binding compounds as hla-agonists and antagonists
11/04/1999WO1999055681A1 Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same
11/04/1999WO1999055680A1 Aryl fused azapolycyclic compounds
11/04/1999WO1999055678A1 Quinoline derivatives
11/04/1999WO1999055677A1 Quinolones used as mrs inhibitors and bactericides
11/04/1999WO1999055676A1 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
11/04/1999WO1999055674A1 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
11/04/1999WO1999055672A2 Antipsychotic indolyl derivatives
11/04/1999WO1999055669A1 Process for the preparation of methyl(2s)-2-[(3r)-3-(n-[tert-butyloxycarbonyl]-amino)-2-oxopyrrolidin-1-yl]propionate
11/04/1999WO1999055668A1 3-arylphenyl sulfide derivatives and insecticides and miticides
11/04/1999WO1999055667A1 N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
11/04/1999WO1999055663A1 Inhibitors of impdh enzyme
11/04/1999WO1999055661A1 Aminomethyl-benzoic ester derivatives as tryptase inhibitors
11/04/1999WO1999055657A1 Novel compounds extracted from vegetable oil useful in pharmaceutics and cosmetics, in particular for inhibiting cell growth
11/04/1999WO1999055388A1 Substituted porphyrins
11/04/1999WO1999055378A1 Method of treating endotoxemia
11/04/1999WO1999055375A1 Stable mitoxantron solutions
11/04/1999WO1999055372A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
11/04/1999WO1999055371A1 Solution containing nicotine
11/04/1999WO1999055359A1 Compositions and methods for extending the action of clostridial neurotoxin
11/04/1999WO1999055357A1 Method for the treatment of fertility disorders
11/04/1999WO1999055355A1 Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
11/04/1999WO1999055347A2 Treatment of papilloma virus infection using a mycobacterium
11/04/1999WO1999055344A1 Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
11/04/1999WO1999055343A1 Cnre binding factors and uses thereof
11/04/1999WO1999055342A1 Therapeutic anti-cold agent containing isomalt as an active ingredient
11/04/1999WO1999055341A1 Transdermal administration of fenoldopam
11/04/1999WO1999055340A1 PHARMACEUTICAL COMPOSITIONS CONTAINING IN COMBINATION AN ARGININE-VASOPRESSIN V1a ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST
11/04/1999WO1999055339A1 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
11/04/1999WO1999055338A1 Treatment of depression and pharmaceutical preparations therefor
11/04/1999WO1999055337A1 Stabile compositions comprising levosimendan and alginic acid
11/04/1999WO1999055336A1 Riluzole and levodopa combinations for treating parkinson's disease
11/04/1999WO1999055335A1 Substituted tricyclic pyrazole derivatives with protein kinase activity
11/04/1999WO1999055334A1 Use of lofexidine for treating chronic pelvic pain in women
11/04/1999WO1999055333A1 Pharmaceutical imidazole combination for locally treating vulvovaginitis and vaginosis
11/04/1999WO1999055332A1 Medicinal compositions
11/04/1999WO1999055331A1 Use of alpha lipoic acid to reduce appetite and/or body weight
11/04/1999WO1999055330A1 Ccr-3 receptor antagonists
11/04/1999WO1999055329A1 Cataract remedy
11/04/1999WO1999055328A1 Fire-resistant non-explosive solid mixtures containing nitroglycerine and water-free lactose
11/04/1999WO1999055327A1 Composition containing polyacrylate, polyterpene, nitroglycerine and possibly polyvinyl acetate
11/04/1999WO1999055326A1 Method of treatment of glutathione deficient mammals
11/04/1999WO1999055325A1 Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof
11/04/1999WO1999055324A1 Ccr-3 receptor antagonists
11/04/1999WO1999055323A1 Use of nmda antagonists for treatment of irritable bowel syndrome
11/04/1999WO1999055322A1 Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
11/04/1999WO1999055321A1 Compounds and methods for treating mitochondria-associated diseases
11/04/1999WO1999055320A1 Oral formulation comprising biguanide and an organic acid
11/04/1999WO1999055319A1 Aerosol formulations of salmeterol xinafoate
11/04/1999WO1999055318A1 Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases
11/04/1999WO1999055317A2 Treatment of advanced decompensated heart failure with nitric oxide donors
11/04/1999WO1999055316A2 Kinase obtained from leishmania
11/04/1999WO1999055313A1 Pellets having a core coated with a lipid lowering agent and a polymer
11/04/1999WO1999055312A2 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
11/04/1999WO1999055307A1 Method of treating the skin with organic acids in anhydrous polymeric delivery systems
11/04/1999WO1999055305A2 Controlled release peroral compositions of levosimendan
1 ... 6417 6418 6419 6420 6421 6422 6423 6424 6425 6426 6427 6428 6429 6430 6431 6432 6433 6434 6435 6436 6437 ... 7860